A Study of Carbon 13-based Deep Labelling of Bone Marrow Cells

Launched by MAYO CLINIC · Jun 30, 2025

Keywords

ClinConnect Summary

This Mayo Clinic study is an observational, cross‑sectional project to understand how bone marrow cells take up nutrients from their surroundings. Researchers will compare people with Monoclonal Gammopathy of Undetermined Significance (MGUS) to healthy volunteers, using a new lab method that labels nutrients with carbon-13 to track how much glucose and other amino acids the cells use. The goal is to see if there is a difference in nutrient uptake between the abnormal, clonal plasma cells seen in MGUS and the normal plasma cells.

Who can join: adults 18 and older. The MGUS group must meet standard MGUS criteria (non‑IgM type) and be able to give informed consent. The study also includes healthy volunteers. Exclusion criteria include inability to consent, having a poor performance status, recent adverse reactions to conscious sedation, ongoing immunosuppressive treatment, or pregnancy. Participation involves blood draws and a bone marrow sample collection as part of study procedures, with no treatment given. The study is currently enrolling by invitation, aiming to enroll about 40 participants, with study activities occurring through 2027. Mayo Clinic in Rochester leads the study (NCT07057583).

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * All Participants:
• • At least age 18 years or older
• • Able to provide informed consent
• * MGUS Cohort:
• • International Myeloma Working Group (IMWG) criteria for the diagnosis of non-IgM MGUS
• Exclusion Criteria:
• * All Participants:
• • Unable to provide consent
• • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) \>1
• • Prior history of adverse events with conscious sedation
• • Ongoing use of immunosuppressive medications
• • All known pregnant and lactating women will be excluded